JENNA BOSCH: Open Payments
NPI 1700208071 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$886 in 51 payments from 8 companies in 2025. Trend: 2023 $350 · 2024 $612 · 2025 $886
Food & beverage: $886
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $256 |
| Amgen Inc. | 10 | $146 |
| ABBVIE INC. | 9 | $139 |
| Novo Nordisk Inc | 5 | $110 |
| Esperion Therapeutics, Inc. | 6 | $94 |
| PFIZER INC. | 3 | $73 |
| Lilly USA, LLC | 2 | $36 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $31 |
Products named: FARXIGA, REPATHA, NEXLETOL, Ozempic, AIRSUPRA, QULIPTA, UBRELVY, ELIQUIS.
Industry payments across AL — which companies pay providers there.
